Omnicell (NASDAQ:OMCL) Updates FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 1.650-1.850 for the period, compared to the consensus EPS estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Analyst Ratings Changes

A number of research analysts have recently weighed in on OMCL shares. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Wells Fargo & Company cut their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. JPMorgan Chase & Co. cut their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Omnicell has an average rating of “Hold” and a consensus target price of $51.00.

Omnicell Trading Up 0.8 %

NASDAQ:OMCL opened at $34.74 on Friday. Omnicell has a one year low of $25.12 and a one year high of $55.75. The business’s 50-day simple moving average is $39.16 and its 200 day simple moving average is $42.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 128.66, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, sell-side analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.